← Leaderboards
Jiang He
University Of California, San Francisco
$3,174,199
Attributed
$4,913,536
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $696.4K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,913,536 · 4
By mechanism
R01$4,482,591 · 3
R21$430,945 · 1
Top collaborators
- Bin Liu6 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Lawrence Fong$19,816,074
- Javier Caravaca$4,172,205
- Anil Parsram Bidkar$185,760
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseBiodistributionCellsLabelRadiolabeledImageIn VitroDrug KineticsIn VivoTumor TissueTreatment EfficacyOrganAntibodiesTumorSchemeResponseTissuesChelating AgentsRadioimmunotherapyDosimetryRadioisotopesToxic EffectImmunoglobulin FragmentsEvaluation
Grant awards (13)
Targeting tumor-specific epitope for imaging and therapy for mesothelioma$696,447
R01 · FY2025 · CA · contact PI
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$546,037
R01 · FY2022 · CA · contact PI
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$557,186
R01 · FY2021 · CA · contact PI
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$559,729
R01 · FY2020 · CA · contact PI
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$543,996
R01 · FY2019 · CA · contact PI
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer$575,279
R01 · FY2018 · CA · contact PI
Novel systemic delivery of siRNA for atherosclerosis$233,445
R21 · FY2015 · HL · contact PI
Novel systemic delivery of siRNA for atherosclerosis$197,500
R21 · FY2014 · HL · contact PI
Targeted liposomal radiotherapy of malignant mesothelioma$195,292
R01 · FY2011 · CA · contact PI
Targeted liposomal radiotherapy of malignant mesothelioma$56,299
R01 · FY2011 · CA · contact PI
Targeted liposomal radiotherapy of malignant mesothelioma$259,432
R01 · FY2010 · CA · contact PI
Targeted liposomal radiotherapy of malignant mesothelioma$259,491
R01 · FY2009 · CA · contact PI
Targeted liposomal radiotherapy of malignant mesothelioma$233,403
R01 · FY2008 · CA · contact PI